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But the Scar Still Exists! The Risk
May Be Lower But Not ZeroWe thank Dr. Pillarisetti and colleagues for their in-
terest in our report (1). However, we disagree with the
conclusions they have drawn from additional analysis
of our data. They argue that patients with primary
prevention implantable cardioverter-deﬁbrillators
(ICDs) who experience no appropriate ICD therapy
and demonstrate improvement of left ventricular
ejection fraction (LVEF) to $40% should routinely
undergo generator replacement (GR). To further
this argument, they have analyzed the event rate
(appropriate ICD therapy) of 2.8% per person-year
that we observed in the group of patients who un-
derwent GR despite improved LVEF and have derived
a number needed to treat (NNT) of 76 to prevent 1
appropriate ICD therapy. They further contend that
the NNT may have been lower if patients who expe-
rienced appropriate ICD therapy despite improve-
ment in LVEF before GR were included. However,
their latter contention is invalid because in our
study these patients fulﬁlled secondary prevention
indications for ICD therapy. This point notwith-
standing, is an NNT of 76 to prevent 1 appropriate ICD
therapy sufﬁcient to justify routine GR?
In the largest trial assessing efﬁcacy of primary
prevention ICD therapy, i.e., SCD-HeFT (Sudden
Cardiac Death in Heart Failure Trial) (2), the NNT with
ICD to prevent 1 death was 20. Similar NNTs have
been shown for other lifesaving advances in cardiol-
ogy that have gained widespread acceptance. For
example, the NNT with primary coronary angioplasty
(versus thrombolytic therapy) to prevent 1 death from
acute myocardial infarction is 10 (3), and the NNT
with beta-blockers in chronic heart failure to prevent
1 death is 15 (4). While it is unclear (and subjective)
what an “acceptable” NNT should be for GR in
recipients of primary prevention ICD, an NNT of 76 to
prevent 1 appropriate device therapy (which is not
synonymous with mortality) is clearly much higherthan what has been shown with other lifesaving car-
diovascular therapies. Furthermore, the potential
risks of the GR procedure must be taken into account.
Data from the REPLACE (Implantable Cardiac Pulse
Generator Replacement) registry show that the major
complication rate for patients undergoing ICD GR
is 5% (5). This would imply that for 1 patient to
receive appropriate ICD therapy after GR, 4 patients
would experience a major complication from the
procedure.
The principle of nonmaleﬁcence necessitates
weighing any lifesaving beneﬁt against the potential
for harm. The latter in patients undergoing ICD GR
includes inappropriate shocks, pocket or device in-
fections, device malfunction, and manufacturer re-
calls. Why an approach of LVEF reassessment and
informed discussion regarding the uncertain beneﬁts
and risks of GR in this patient population, as sug-
gested by our study, is perceived as “bold and
sweeping” by Dr. Pillarisetti and colleagues remains
unclear to us. In any situation in which there is sig-
niﬁcant uncertainty regarding the beneﬁts of a
treatment, deferring to patient preference after
sharing all the relevant information without bias is, in
our opinion, the optimal approach.Vinay Kini, MD
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